IHS Chemical Week

EnviroTech :: Biotech

Boehringer Ingelheim Launches Venture Capital Fund

5:12 AM MDT | March 31, 2010 | Deepti Ramesh

Boehringer Ingelheim (Ingelheim, Germany) says it has launched a corporate venture capital fund, Boehringer Ingelheim Venture Fund (BIVF), which aims to invest in biotechnology and start-up companies that provide groundbreaking therapeutic approaches and technologies to help drive innovation in medical science. These will include new therapeutic concepts including stem cells and RNA silencing, as well as new-generation vaccines, new-generation protein or antibody technologies, new molecular targets, and/or first-in-class lead compounds, as well as disease-related...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers




contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa